Skip to content
lifestyle.chroniccities.us
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Tarsus Pharmaceuticals, Inc
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
July 13, 2026
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
July 8, 2026
Tarsus to Participate in Upcoming Investor Conferences
May 28, 2026
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
May 14, 2026
Tarsus to Participate in Upcoming Investor Conferences
May 7, 2026
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
May 6, 2026
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
April 29, 2026
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
March 31, 2026
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
March 23, 2026
Tarsus to Participate in Upcoming Investor Conferences
February 26, 2026
1
2
Next Page
→